NCT07485205招募中不适用
Establishing Normative Urodynamics Parameters for the Glean Urodynamics System in Healthy Adults
Bright Uro4 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2026年3月31日最近更新:
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 72
- 试验地点
- 4
- 主要终点
- Range of vesical pressure (Pves)
研究概览
简要总结
A prospective, open-label, single arm interventional trial to establish normative reference ranges for urodynamics parameters in healthy adult participants using using the Glean Urodynamics System.
详细描述
Subjects will have the Glean Urodynamics System inserted for an in-clinic ambulatory monitoring period. Afterward, they will be discharged with the Glean Bladder Sensor in place for continued monitoring outside the clinic, not exceeding 24 hours. The sensor will be removed within 24 hours of insertion. Subjects will receive a follow-up phone call 7 days post-removal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female adults ages 18 to 45 years.
- •Patient is able to read, write, and communicate in English.
- •Patient is able to provide informed consent.
- •Patient owns, can independently operate, and is willing to use a smart device for study data collection purposes
排除标准
- •Patient with any prior pregnancy (gravida ≥1), is currently pregnant (as confirmed by urine pregnancy test or medical history), or intends to become pregnant during the study period.
- •Patient has one or more symptoms indicative of a symptomatic urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and/or dysuria).
- •Patient has a known history of urological conditions (e.g., recurrent UTIs, incontinence, symptomatic benign prostatic hyperplasia, neurogenic bladder, interstitial cystitis, urinary retention, any genitourinary cancer).
- •Patient has a known history of neurological conditions that can affect central nervous system function.
- •Patients with a current or prior diagnosis of diabetes mellitus (Type 1 or Type 2).
- •Patient is currently taking medications that may affect urological functions (e.g., diuretics, anticholinergics, alpha-blockers).
- •Patient has abnormal urinary habits if one or more of the following bladder events are reported on any day of the 3-day bladder diary: urinary frequency ≥ 8 times/day, ≥ 1 nocturia episode, ≥ 1 leak event, or ≥ 1 urgency event.
- •Patient has a total score on the Lower Urinary Tract Dysfunction Research Network Symptom Index-10 (LURN SI-10) questionnaire greater than 0; a total score of 1 is acceptable only if the sole positive response is urinary frequency of 4-7 times per day.
- •Patient has a urostomy and/or colostomy.
- •Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and/or bladder wall) that the principal investigator deems might compromise the placement or retention of the Glean sensors during the study (e.g., strictures).
- •Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen).
- •Patient would not be appropriate for this study as determined by the Principal Investigator.
研究组 & 干预措施
Glean Urodynamics System
Experimental
Glean Urodynamics System including a bladder pressure sensor, abdominal pressure sensor, in-clinic uroflowmeter, and software apps.
干预措施: Glean Urodynamics System (Device)
结局指标
主要结局
Range of vesical pressure (Pves)
时间窗: Periprocedurally
Range of vesical pressure (Pves) in cm H2O as measured by the Glean Bladder Sensor
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
招募中
不适用
Ambulatory Long Length URodynamics EvaluationBenign Prostatic HyperplasiaNCT07425015Bright Uro101
尚未招募
不适用
Is Treatment With FMS Tesla Chair Equal to Physiotherapy in First and Second-degree Urinary Incontinence?NCT07265700Kantonsspital Winterthur KSW100
尚未招募
不适用
FANS vs Standard Ureteral Access Sheath in fURSNCT07463157IRCCS San Raffaele134
招募中
4 期
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder CancerNCT07474519Ohio State University Comprehensive Cancer Center40
尚未招募
不适用
A Phase 3, Open label, Randomized and Controlled Study of Disitamab Vedotin with Pembrolizumab Versus platinum containing chemotherapy in participants with Urothelial cancer that Expresses HER2 that has spread through the body or spread near where it started.CTRI/2025/07/091091Seagen Inc., a wholly owned subsidiary of Pfizer400